As expected, the UK's Competition and Markets Authority is referring the proposed Illumina acquisition of PacBio for an in-depth Phase 2 investigation.
The study used a variety of sequencing and mapping technologies, including from Illumina, Pacific Biosciences, 10X Genomics, Bionano Genomics, and Oxford Nanopore.
Five early customers are currently operating the Sequel II, which promises an eightfold increase in throughput, making reference genome sequencing feasible.
The US Court of Appeals upheld a previous ruling by the International Trade Commission that found Oxford Nanopore's products do not infringe on PacBio's patents.
PacBio reported that both its Q4 and full year 2018 revenues fell, but that it had launched the next version of its single-molecule sequencing platform in early access.
A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.
